Abstract:Background: Charcot-Marie-Tooth subtype 2A (CMT2A) is an autosomal dominant single-gene motor sensory neuropathy that is caused by mitofusin 2 (Mfn2) mutation. It is generally believed that CMT2A involves mitochondrial fusion disruption. However, how to ameliorate the loss of mitochondrial membrane fusion in CMT2A remains unclear. Methods: In vivo and in vitro mouse models harboring the Mfn2H165R, Mfn2G176S and Mfn2R364W mutations were constructed. We first examined mitochondrial damage and pathophysiological features of Mfn2 mutations. Then, we started with the proteins Mfn2 and Opa1 to analyze the mechanism of mitochondrial aggregation and fragmentation. Findings: Studies have shown that, in Mfn2R364W, Mfn2G176S, Mfn2H165R/+ mutations, fragmentation of mitochondria is mainly mediated by optic atrophy 1 (Opa1) hydrolytic cleavage rather than loss of Mfn2, as Mfn2 expression is activated by Bax translocation. While in Mfn2 H165R/H165R mutation, Opa1 hydrolytic cleavage and Mfn2 loss induced mitochondrial fragmentation and aggregation. Furthermore, in all mutations, hydrolytic cleavage of Opal is mediated by dissipation of mitochondrial membrane potential (MMP), apoptosis, and consequent uncoupling of oxidative phosphorylation. Interpretation: Mitochondrial aggregation and hydrolytic cleavage of Opa1 are two independent pathways of CMT2A pathogenesis: Opa1-induced mitochondrial fragmentation affects the stability of mitochondrial DNA and causes mitochondrial dysfunction, which ultimately leads to CMT2A; mitochondrial transport defect caused by loss of Mfn2 also contributes to the pathogenesis of CMT2A. Funding Information: This study was financially supported by a grant from the Special Funds for Cultivation and Breeding of New Transgenic Organisms (No. 2016ZX08006003), the Program for JLU Science and Technology Innovative Research Team (2017TD-28).Declaration of Interests: The authors declare no competing interest.Ethics Approval Statement: All animal studies were approved by the Animal Welfare and Research Ethics Committee of Jilin University, and all procedures were conducted in strict accordance with the Guide for the Care and Use of Laboratory Animals. The mice were euthanized at humane end-points or the predetermined end of the experiment. The animal carcasses were treated in a standardized and respectful manner after the experiment.

CMT2A-linked MFN2 mutation, T206I promotes mitochondrial hyperfusion and predisposes cells towards mitophagy

Mfn2R364W, Mfn2G176S, and Mfn2H165R mutations drive Charcot-Marie-Tooth type 2A disease by inducing apoptosis and mitochondrial oxidative phosphorylation damage

MFN2 mutations in Charcot–Marie–Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics

Restoring Mitofusin Balance Prevents Axonal Degeneration in a Charcot-Marie-Tooth Type 2A Model.

Mitofusin 1 overexpression rescues the abnormal mitochondrial dynamics caused by the Mitofusin 2 K357T mutation in vitro

Mutations in MTO2 Related to Trna Modification Impair Mitochondrial Gene Expression and Protein Synthesis in the Presence of a Paromomycin Resistance Mutation in Mitochondrial 15 S Rrna

Deregulation of Mitochondrial Fusion and Fission in Neurodegenerative Diseases

A human mitofusin 2 mutation can cause mitophagic cardiomyopathy

Structural Insights of Human Mitofusin-2 into Mitochondrial Fusion and CMT2A Onset

The MFN2 Q367H variant from a patient with late-onset distal myopathy reveals a novel pathomechanism connected to mtDNA-mediated inflammation

MFN1 Augmentation Prevents Retinal Degeneration in a Charcot-Marie-Tooth Type 2A Mouse Model

A novel variant in MFN2 linked to a lethal disorder of neonatal onset

Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A

A cellular assay to determine the fusion capacity of MFN2 variants linked to Charcot-Marie-Tooth type 2A

Exome Sequencing Reveals a Novel MFN2 Missense Mutation in a Chinese Family with Charcot-Marie-Tooth Type 2A

An Integrative Analysis of Genotype-Phenotype Correlation in Charcot Marie Tooth Type 2A Disease with MFN2 Variants: A Case and Systematic Review

Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A

Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives

MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A

Mitochondria Dysfunction in Charcot Marie Tooth 2B Peripheral Sensory Neuropathy

Hydrolytic Cleavage of Optic Atrophy 1 Drives the Pathogenesis of CMT2A Neuropathy Caused by Mfn2 Mutation